Skip to content

PT-141 (Bremelanotide)

FDA-Approved• Prescribable
peptideInjection

Boosts sexual desire through melanocortin receptors in the brain, not blood vessels. FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women.

Key Facts

  • Classification
    PT-141 (Bremelanotide) selectively activates MC4R in the CNS to initiate sexual arousal through dopaminergic pathways.
  • Primary Benefits
    Mood & Anxiety (4/10) · Fertility & Hormones (3/10)
  • Administration
    Injection
  • Typical Dose
    1.75 mg subq about 45 minutes before you need it. Don't use more than once in 24 hours, and it's not meant for daily use. FDA-approved route is subcutaneous injection only.
  • Evidence Strength
    Strong — 20 peer-reviewed studies referenced · Community sentiment 8/10
  • Stacks Well With
    Kisspeptin-10
  • Legal Status
    FDA-Approved · prescription required

Quick Facts

From price
$35
Type
peptide
Administration
Injection
Evidence
strong
Studies referenced
20
Community sentiment
8/10
Stacks with
1 peptide
Regulatory
FDA-Approved

Top benefits

😌 Mood & Anxiety
4/10
🧬 Fertility & Hormones
3/10
View PricingCompare
1

Week 1–2

Effects are acute — sexual arousal and desire increase within 1-4 hours of dosing. Not used continuously. Nausea is common on first use.

2

Week 3–6

Continued as-needed use. Effects remain consistent with each dose. Side effects typically diminish with experience. Optimal dosing established.

3

Week 8+

Sustained efficacy with as-needed dosing. No cumulative benefits — mechanism is acute CNS activation per dose.

Common Side Effects

Nausea (very common, especially first dose)FlushingHeadacheNasal congestionElevated blood pressure (transient)Skin darkening with repeated use
Tolerance: Minimal — as-needed dosing prevents tolerance. Avoid more than 8 doses per month
Cycling: Use as needed, max 1 dose per 24 hours. No more than 8 doses per month. No cycling required.

Scientific Overview

PT-141 (Bremelanotide) selectively activates MC4R in the CNS to initiate sexual arousal through dopaminergic pathways. FDA-approved as Vyleesi for HSDD in premenopausal women. Acts centrally rather than on peripheral vasculature.

Dosing

1.75 mg subq about 45 minutes before you need it. Don't use more than once in 24 hours, and it's not meant for daily use. FDA-approved route is subcutaneous injection only.

Reconstitution, storage, injection sites & timing

Benefit Profile

😌 Mood & Anxiety
4/10
🧬 Fertility & Hormones
3/10
Medical oversight requiredNot safe during pregnancy· 4 contraindications